AXGT Stock Price, News & Analysis

AXGT

Company Description

AXGT (Nasdaq: AXGT) is a publicly traded company.

AXGT stock has declined 59.9% over the past year.

This page provides a comprehensive overview of AXGT stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-59.85%

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

AXGT (AXGT) stock. Over the past 12 months, the stock has lost 59.9%.

Latest News

View All

November 10, 2020

+6.53%

Axovant Gene Therapies Announces Name Change to Sio Gene Therapies

November 9, 2020

+4.19%

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases

clinical trial fda approval

October 29, 2020

-41.64%

Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020

conferences

October 22, 2020

+1.16%

Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020

conferences

October 13, 2020

0.00%

Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease

October 9, 2020

+3.91%

Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis

AXGT has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial, fda approval, conferences, management, partnership. View all AXGT news →

SEC Filings

View All

No SEC filings available for AXGT.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months